Solid Biosciences (SLDB) Stock Price, Quote, News & History | Benzinga

Solid Biosciences Inc (SLDB) Stock Price, Quote, News & History

SLDBNASDAQ

Trade with Public

Trade with Public

$9.77

-0.36-3.55%

At close: Aug 28, 5:00 PM EST

$9.77

N/A

After Hours: Aug 28, 4:00 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$10.02

Close

$9.77

Volume / Avg.

621.52K / 1.59M

Day Range

$9.72 - $10.10

52 Wk Range

3.79 - 11.45

Market Cap

$1.05B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

58

Short Interest

17.62%

Days to Cover

19.61

Recent Solid Biosciences Inc News

Nvidia To Rally Around 146%? Here Are 10 Top Analyst Forecasts For Thursday

Wall Street analysts changed outlook on top names: Evercore raised Salesforce target, Needham raised Nutanix target, Ascendiant raised PAVmed target, Cantor raised Okta target, Piper raised Veeva target, Cantor boosted Solid Biosciences target, BTIG raised Crowdstrike target, Cantor cut Dycom target.

Avi Kapoor

Airsculpt Technologies, Barrick Mining And Other Big Stocks Moving Lower In Monday’s Pre-Market Session

Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% after reporting Q2 results in-line with estimates. Other stocks moving lower in pre-market trading include NAMI, BNED, YXT, TENX, MSC, B, VRSK, XFOR, HELP, and SLDB.

Avi Kapoor

Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

U.S. stock futures mostly higher, Nasdaq futures gain 100+ points. Sophia Genetics (SOPH) falls after pricing public offering of $50M. Other stocks decline in pre-market.

Avi Kapoor

This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday

Wall Street analysts changed ratings on top stocks. For insights on changes, see analyst ratings page. RBRK stock: buy or not? Analysts weigh in.

Avi Kapoor

Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned

Solid Biosciences stock fell 8% after new SGT-003 Duchenne trial data. Investors remain cautious despite promising results and FDA plans.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-186.84M

Investing Cash Flow (TTM)

-87.09M

Financing Cash Flow (TTM)

293.82M

Free Cash Flow (TTM)

-187.81M

Capital Expenditure (TTM)

-965.00K

Net Change in Cash (TTM)

19.88M

Analyst Trends and Forecast

8

Mar

3

May

1

Jun

2

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.3

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$690.07M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

2.90

Earnings Yield % (TTM)

-18.66%

Earnings Yield % (FWD)

-16.09%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$3.49

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$446.00K

Total Cash

$159.39M

Debt to Equity

0.05

Issuance of Debt (TTM)

-$446.00K

Repayment of Debt (TTM)

-$446.00K

Key Statistics

Open

$10.02

Close

$9.77

Volume / Avg.

621.52K / 1.59M

Day Range

$9.72 - $10.10

52 Wk Range

3.79 - 11.45

Market Cap

$1.05B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

58

Short Interest

17.62%

Days to Cover

19.61

About

Sector

Health Care

Industry

Biotechnology

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Solid Biosciences (SLDB) stock?

A

You can purchase shares of Solid Biosciences (NASDAQ:SLDB) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Solid Biosciences (SLDB) competitors?

A

Other companies in Solid Biosciences’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Solid Biosciences (SLDB) stock?

A

Solid Biosciences has a consensus price target of $17.40.

Q

What is the current price for Solid Biosciences (SLDB)?

A

The stock price for Solid Biosciences (NASDAQ: SLDB) is $9.77 last updated August 28, 2026 at 4:00 PM EDT.

Q

Does Solid Biosciences (SLDB) pay a dividend?

A

There are no upcoming dividends for Solid Biosciences.

Q

When is Solid Biosciences (NASDAQ:SLDB) reporting earnings?

A

Solid Biosciences does not have any upcoming earnings scheduled.

Q

Is Solid Biosciences (SLDB) going to split?

A

There is no upcoming split for Solid Biosciences.

Q

What sector and industry does Solid Biosciences (SLDB) operate in?

A

Solid Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.